

April 11, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

Hand Carry
Art Unit: 1626
Crystal Mall 1
Reception 7th Floor
Attn: Examiner E. Sackey

Re: U.S. Utility Patent Application
Appl. No. 09/252,486; Filed: February 18, 1999
For: Microencapsulated 3-Piperidinyl-Substituted
1,2-Benzisoxazoles and 1,2-Benzisothiazoles
Inventors: Mesens *et al.*
Our Ref: 00166.0051.US04

RECEIVED
COMMUNICATIONS SECTION
APR 11 PM 3:41

Sir:


Transmitted herewith for appropriate action by the U.S. Patent and Trademark Office (PTO) are the following documents:

1. Form PTO-1083 (in duplicate);
2. Reply Under 37 C.F.R. § 1.111; and
3. Return post card receipt.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 00166.0051.US04. A duplicate copy of this letter is enclosed.

Respectfully submitted,


Andrea G. Reister (Reg. No. 36,253)

Enclosures

HOWREY SIMON ARNOLD & WHITE, LLP

Box No. 34

1299 Pennsylvania Avenue, N.W.

Washington, D.C. 20004-2402

(202) 783-0800

FORM PTO-1083

Attorney Docket No. 00166.0051.US04

In re application of **Mesens et al.**

Appl. No. **09/252,486**

Filed: **February 18, 1999**

For: **Microencapsulated 3-Piperidinyl-Substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles**

THE ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

- Small entity status of this application under 37 CFR §§ 1.9 and 1.27 has been established by a statement previously submitted.
- A statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.
- xx No additional claim fee is required.

The claim fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra
Total Claims	* 13	MINUS	** 20	= 0
Indep. Claims	* 1	MINUS	** 3	= 0
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM				

SMALL ENTITY	
Rate	Addit. Fee
x 9 =	\$ 00.00
x 39 =	\$ 00.00
+130 =	\$ 00.00
Total Addit. Fee	\$ 00.00

OTHER THAN A SMALL ENTITY	
Rate	Addit. Fee
x 18 =	\$ 00.00
x 78 =	\$ 00.00
+ 260 =	\$ 00.00
TOTAL	\$ 00.00

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

- Please charge my Deposit Account No. 08-3038 in the amount of \$ * referencing docket number *. A duplicate copy of this sheet is attached.


- Check number * in the amount of \$ *.00 is attached.

xx The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 08-3038 referencing docket number 00166.0051.US04. A duplicate copy of this sheet is attached.

xx Any filing fees under 37 CFR § 1.16 for the presentation of extra claims.

xx Any patent application processing fees under 37 CFR § 1.17.

Date: April 11, 2000


Andrea G. Reister (Reg. No. 36,253)